Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

25
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

20
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
20

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exercise performance in patients with heart failure and impaired iron transport: a single-centre retrospective study.

BMJ open·2026
Same author

Beyond the slope: prognostic utility of the VE/VCO<sub>2</sub> intercept in chronic heart failure.

Open heart·2026
Same author

Cardiac abnormalities in a young athlete with severe pectus excavatum: a case report of a diagnostic loop between anatomical distortion and cardiomyopathy.

European heart journal. Case reports·2026
Same author

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.

Cancer treatment reviews·2026
Same author

Target symptom-guided prescribing in home-based specialist palliative care: prospective quality improvement study.

BMJ supportive & palliative care·2026
Same author

Manufacturing 3D aortic root models for in vitro assessment of calcific aortic valve stenosis.

Annals of biomedical engineering·2026
Same journal

Large-Eddy Simulation of the FDA Benchmark Blood Pump: Validation Against Experiments and Implications for Turbulent Flow Mechanisms.

Artificial organs·2026
Same journal

The Warm Revolution: A Meta-Analysis of DCD Versus DBD Liver Transplant Outcomes in the Normothermic Machine Perfusion Era.

Artificial organs·2026
Same journal

Toward Optimal Remote Monitoring in LVAD Recipients: Remaining Challenges Beyond Feasibility.

Artificial organs·2026
Same journal

Advancing Organ Preservation and Perfusion: Introducing the International Society of Organ Preservation and Perfusion Therapy (ISOPPT).

Artificial organs·2026
Same journal

Short Inter-Treatment Interval Treatment With Artificial Liver Support System Reduces 90-Day Transplant-Free Mortality in Patients With Hepatitis B Virus-Related Acute-On-Chronic Liver Failure: A Retrospective Observational Study.

Artificial organs·2026
Same journal

Extracorporeal Albumin Dialysis (OPAL) as Novel Therapeutic Bridging Option in Posthepatectomy Liver Failure.

Artificial organs·2026
See all related articles

Related Experiment Video

Updated: Sep 4, 2025

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.5K

Technology and technique for left ventricular assist device optimization: A Bi-Tech solution.

Vincenzo Tarzia1, Matteo Ponzoni1, Gabriele Di Giammarco2

  • 1Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Artificial Organs
|July 22, 2022
PubMed
Summary
This summary is machine-generated.

The Jarvik 2000 heart pump with a cone-bearing design and minimally invasive surgery significantly improved survival rates for LVAD patients. This combined approach also reduced the risk of cardiovascular events, enhancing patient outcomes.

Keywords:
Jarvik 2000cone-bearingminimally-invasive

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.0K

Related Experiment Videos

Last Updated: Sep 4, 2025

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.5K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.0K

Area of Science:

  • Cardiovascular Surgery
  • Biomedical Engineering
  • Medical Devices

Background:

  • Investigated the synergistic effect of the Jarvik 2000 cone-bearing design and minimally invasive surgery on Left Ventricular Assist Device (LVAD) patient outcomes.
  • Evaluated the impact of technological advancements in LVADs on patient survival and adverse event rates.

Purpose of the Study:

  • To assess the combined benefits of the Jarvik 2000's cone-bearing design and minimally invasive implantation techniques.
  • To compare outcomes across different LVAD configurations and surgical approaches.

Main Methods:

  • Retrospective review of 150 adult end-stage heart failure patients from the Jarvik 2000 Italian Registry (October 2008-October 2016).
  • Patients categorized into three groups: pin-bearing/conventional, cone-bearing/conventional, and cone-bearing/minimally invasive.
  • Analysis of discharge rates, transplantation, LVAD explantation, survival rates, and adverse event incidence.

Main Results:

  • Overall 1-year survival rates were 58% (Group 1), 64% (Group 2), and 74% (Group 3), with a statistically significant difference (p=0.034).
  • The cone-bearing design with minimally invasive surgery (Group 3) showed a significantly lower cumulative incidence rate for adverse events (22.1 per 100 patient-years) compared to the pin-bearing design (p=0.046).
  • Discharge rates were comparable across groups (73%, 69%, 72%), but long-term survival and safety were notably improved in Group 3.

Conclusions:

  • The combination of the Jarvik 2000's cone-bearing design and minimally invasive surgery significantly enhances survival and reduces cardiovascular event risk in LVAD patients.
  • Integrating advanced LVAD technology with refined surgical techniques offers a superior approach for managing end-stage heart failure.
  • This study highlights the importance of optimizing both device design and surgical methodology for improved LVAD therapy outcomes.